IRON
Disc Medicine, Inc. NASDAQ Listed Aug 12, 2020$67.52
After hrs
$69.59
+1.95%
Mkt Cap $2.6B
52w Low $40.00
46.3% of range
52w High $99.50
50d MA $65.07
200d MA $71.82
P/E (TTM)
-11.1x
EV/EBITDA
-13.1x
P/B
3.2x
Debt/Equity
0.0x
ROE
-28.7%
P/FCF
-15.5x
RSI (14)
—
ATR (14)
—
Beta
2.54
50d MA
$65.07
200d MA
$71.82
Avg Volume
651.7K
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
321 Arsenal Street · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | -1.69 | -1.62 | +4.1% | 67.91 | -0.6% | -1.9% | -2.0% | -5.2% | -10.0% | -11.1% | — |
| Nov 6, 2025 | AMC | -1.48 | -1.77 | -19.6% | 87.00 | +0.0% | -3.6% | -3.9% | -1.1% | -1.1% | +0.0% | — |
| Aug 7, 2025 | AMC | -1.17 | -1.58 | -35.0% | 57.07 | -0.9% | +1.7% | +2.7% | +3.4% | +7.1% | +6.4% | — |
| May 7, 2025 | AMC | -0.99 | -1.02 | -3.0% | 43.55 | -0.5% | +1.7% | +1.6% | +7.0% | +6.4% | +5.0% | — |
| Feb 27, 2025 | AMC | -1.06 | -0.98 | +7.5% | 54.50 | -0.2% | +3.1% | -0.3% | +1.5% | +4.4% | +1.8% | — |
| Nov 12, 2024 | AMC | -0.98 | -0.89 | +9.2% | 63.26 | +1.3% | -0.3% | -4.1% | -6.0% | -9.3% | -5.9% | — |
| Aug 8, 2024 | AMC | -1.11 | -1.03 | +7.2% | 42.85 | +1.2% | +0.6% | +5.1% | +7.0% | +5.7% | +12.8% | — |
| May 9, 2024 | AMC | -1.00 | -1.09 | -9.0% | 30.77 | +0.3% | -1.3% | +0.8% | +3.5% | +3.5% | +3.7% | — |
| Mar 21, 2024 | AMC | -0.75 | -0.97 | -29.3% | 61.41 | -1.1% | -1.3% | -3.1% | -1.8% | -1.5% | +1.4% | — |
| Nov 9, 2023 | AMC | -0.75 | -0.58 | +22.7% | 48.41 | +0.3% | +0.3% | +2.4% | +6.6% | +8.3% | -0.1% | — |
| Aug 11, 2023 | AMC | -0.88 | -0.74 | +15.9% | 52.92 | +3.7% | -1.4% | +2.3% | +0.1% | -3.4% | -2.1% | — |
| May 15, 2023 | AMC | -0.62 | -1.20 | -93.5% | 32.00 | -1.1% | +4.3% | +6.4% | +4.9% | +5.6% | +4.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | Wells Fargo | Maintains | Overweight → Overweight | — | $66.62 | $64.85 | -2.7% | -0.1% | -3.4% | -8.3% | -9.4% | -8.2% |
| Feb 27 | Truist | Maintains | Buy → Buy | — | $67.91 | $67.49 | -0.6% | -1.9% | -2.0% | -5.2% | -10.0% | -11.1% |
| Feb 17 | Wedbush | Maintains | Outperform → Outperform | — | $55.95 | $55.67 | -0.5% | +17.2% | +15.2% | +13.2% | +9.7% | +14.4% |
| Feb 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $55.95 | $55.67 | -0.5% | +17.2% | +15.2% | +13.2% | +9.7% | +14.4% |
| Feb 17 | Stifel | Maintains | Buy → Buy | — | $55.95 | $55.67 | -0.5% | +17.2% | +15.2% | +13.2% | +9.7% | +14.4% |
| Feb 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $55.95 | $55.67 | -0.5% | +17.2% | +15.2% | +13.2% | +9.7% | +14.4% |
| Feb 17 | BMO Capital | Maintains | Outperform → Outperform | — | $55.95 | $55.67 | -0.5% | +17.2% | +15.2% | +13.2% | +9.7% | +14.4% |
| Dec 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $92.00 | $90.90 | -1.2% | -0.6% | -4.9% | -1.7% | -13.0% | -13.5% |
| Nov 10 | Truist | Maintains | Buy → Buy | — | $83.85 | $85.05 | +1.4% | -0.3% | +2.6% | +2.6% | +3.8% | +7.3% |
| Oct 30 | Morgan Stanley | Maintains | Overweight → Overweight | — | $85.00 | $85.87 | +1.0% | +0.9% | +1.4% | -0.4% | +1.2% | +3.9% |
| Oct 17 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $74.36 | $85.50 | +15.0% | +21.0% | +17.2% | +15.9% | +17.3% | +12.5% |
| Oct 17 | Wedbush | Maintains | Outperform → Outperform | — | $74.36 | $85.50 | +15.0% | +21.0% | +17.2% | +15.9% | +17.3% | +12.5% |
| Oct 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $74.36 | $85.50 | +15.0% | +21.0% | +17.2% | +15.9% | +17.3% | +12.5% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $59.86 | $60.00 | +0.2% | -1.7% | -2.8% | -1.9% | -0.2% | +0.8% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.17 | $53.97 | +1.5% | +3.0% | +0.4% | -0.4% | +5.1% | +9.1% |
| Jun 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.02 | $51.11 | -1.7% | -3.8% | -3.7% | -0.8% | -0.7% | +5.7% |
| May 12 | BMO Capital | Maintains | Outperform → Outperform | — | $44.24 | $46.18 | +4.4% | +5.4% | +4.8% | +3.4% | +6.4% | +8.7% |
| Mar 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $51.27 | $51.47 | +0.4% | +3.0% | +4.8% | +3.8% | +1.9% | +4.7% |
| Mar 3 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $56.18 | $56.18 | +0.0% | -3.3% | -1.5% | +1.3% | -1.2% | -0.9% |
| Jan 24 | Stifel | Maintains | Buy → Buy | — | $56.99 | $57.24 | +0.4% | +0.8% | -1.8% | -3.9% | -1.9% | -2.4% |
| Jan 22 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $60.52 | $58.00 | -4.2% | -3.3% | -5.8% | -5.1% | -7.5% | -9.5% |
| Jan 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.25 | $58.50 | +0.4% | +3.9% | +0.4% | -2.2% | -1.4% | -3.9% |
| Dec 10 | Stifel | Maintains | Buy → Buy | — | $64.66 | $65.61 | +1.5% | +4.3% | +2.0% | -0.6% | +0.4% | +2.4% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $64.82 | $65.84 | +1.6% | -0.2% | +4.1% | +1.7% | -0.8% | +0.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.26 | $64.08 | +1.3% | -0.3% | -4.1% | -6.0% | -9.3% | -5.9% |
| Nov 5 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $58.25 | $60.07 | +3.1% | +11.2% | +11.2% | +8.7% | +11.6% | +14.3% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.25 | $60.07 | +3.1% | +11.2% | +11.2% | +8.7% | +11.6% | +14.3% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.01 | $46.36 | +0.8% | +0.4% | -0.2% | -0.9% | -2.6% | +2.4% |
| Oct 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.99 | $47.77 | -0.5% | -0.7% | +0.0% | +5.2% | +5.4% | +5.8% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $48.58 | $48.36 | -0.5% | -1.0% | -3.4% | -2.9% | -1.5% | -1.1% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.79 | $47.41 | -0.8% | -0.2% | -0.9% | -0.3% | +1.7% | +0.7% |
| Aug 9 | Wedbush | Maintains | Outperform → Outperform | — | $42.85 | $43.36 | +1.2% | +0.6% | +5.1% | +7.0% | +5.7% | +12.8% |
| Jul 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.97 | $46.83 | -0.3% | -2.5% | -0.1% | +0.4% | +4.8% | +2.0% |
| Jun 17 | BMO Capital | Maintains | Outperform → Outperform | — | $46.27 | $46.62 | +0.8% | -3.0% | -5.9% | -10.8% | -4.5% | -2.8% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.16 | $39.16 | +0.0% | +18.2% | +14.6% | +11.2% | +5.3% | +12.8% |
| May 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.28 | $34.74 | +1.3% | +1.1% | -0.4% | +1.0% | -1.0% | +5.8% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.84 | $32.81 | +3.0% | +0.1% | +0.3% | +1.1% | +1.7% | -1.8% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.77 | $30.85 | +0.3% | -1.3% | +0.8% | +3.5% | +3.5% | +3.7% |
| May 10 | Raymond James | Maintains | Outperform → Outperform | — | $30.77 | $30.85 | +0.3% | -1.3% | +0.8% | +3.5% | +3.5% | +3.7% |
| Apr 8 | Stifel | Maintains | Buy → Buy | — | $30.10 | $30.81 | +2.4% | +5.6% | +6.6% | +4.7% | +6.4% | +5.7% |
| Apr 2 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $34.21 | $33.00 | -3.5% | -6.4% | -10.8% | -13.8% | -12.0% | -7.1% |
| Apr 2 | BMO Capital | Maintains | Outperform → Outperform | — | $34.21 | $33.00 | -3.5% | -6.4% | -10.8% | -13.8% | -12.0% | -7.1% |
| Apr 2 | Stifel | Maintains | Buy → Buy | — | $34.21 | $33.00 | -3.5% | -6.4% | -10.8% | -13.8% | -12.0% | -7.1% |
| Apr 1 | Raymond James | Downgrade | Strong Buy → Outperform | — | $62.26 | $26.50 | -57.4% | -45.1% | -48.6% | -51.0% | -52.6% | -51.7% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $62.26 | $26.50 | -57.4% | -45.1% | -48.6% | -51.0% | -52.6% | -51.7% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $61.41 | $60.76 | -1.1% | -1.3% | -3.1% | -1.8% | -1.5% | +1.4% |
| Mar 12 | Stifel | Maintains | Buy → Buy | — | $64.42 | $64.75 | +0.5% | -1.2% | +1.6% | -2.2% | -4.1% | +2.5% |
| Feb 29 | BMO Capital | Maintains | Outperform → Outperform | — | $65.14 | $66.56 | +2.2% | +5.4% | +15.6% | +13.3% | +6.0% | +1.4% |
| Dec 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $58.70 | $58.71 | +0.0% | -2.9% | -0.7% | -1.0% | +3.9% | -1.3% |
| Dec 19 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $58.53 | $56.99 | -2.6% | +0.3% | -2.6% | -0.4% | -0.7% | +4.2% |
No insider trades available.
8-K · 2.02
!! High
Disc Medicine, Inc. -- 8-K 2.02: Earnings Results
Disc Medicine reported Q1 2026 financial results and provided a corporate update, allowing investors to assess the company's operational performance and strategic direction going forward.
May 5
8-K
Disc Medicine, Inc. -- 8-K Filing
I cannot provide a meaningful one-sentence analysis based on this filing summary, as it lacks substantive information about any material event, transaction, or business development that would affect investor decisions.
Feb 27
8-K
Disc Medicine, Inc. -- 8-K Filing
Disc Medicine (IRON) reported Q4 and full-year 2025 results, reaffirming confidence in its bitopertin program and Phase 3 APOLLO study for hematologic disease treatment.
Feb 26
8-K · 7.01
! Medium
Disc Medicine, Inc. -- 8-K 7.01: Regulation FD Disclosure
Disc Medicine's bitopertin NDA for erythropoietic protoporphyria received a Complete Response Letter from the FDA, requiring additional work before approval can be reconsidered.
Feb 17
8-K · 8.01
!! High
Disc Medicine, Inc. -- 8-K 8.01: Material Event / Announcement
Disc Medicine received an FDA Complete Response Letter for its bitopertin EPP treatment application, requiring additional work before potential approval and delaying commercialization timelines for investors.
Feb 13
Data updated apr 25, 2026 4:16pm
· Source: massive.com